The Calcium Channel Blocker Controversy.
スポンサーリンク
概要
- 論文の詳細を見る
A major controversy about the safety of calcium channel blockers (CCBs) has arisen since the publication of a case-control study showing that hypertensives who suffered an acute myocardial infarction (MI) were more likely than hypertensives who had not had an MI to be taking one of these (short-acting) agents than other antihypertensive agents. This study was accompanied by a republication of older studies showing that large doses of short-acting nifedipine given to post-MI patients increased their mortality rate. The danger of massive doses of short-acting nifedipine in a post-MI patient is real but irrelevant to current practice. On the other hand, the putative dangers of short-acting CCBs in the treatment of hypertension do not apply to the current use of long-acting CCBs. Therefore the scare over their use is both irrational and unfortunate. (Hypertens Res 1996; 19: 57-64)
- 日本高血圧学会の論文
日本高血圧学会 | 論文
- Telmisartan treatment decreases Visceral Fat Accumulation and improves Serum Levels of Adiponectin and Vascular Inflammation Markers in Japanese Hypertensive Patients.
- The Effects of Verapamil SR and Bisoprolol on Reducing the Sympathetic Nervous System's Activity.
- The Role of Renal Dopamine in the Reduction of High Blood Pressure by β1-Selective β-Blocker with Intrinsic Sympathomimetic Activity in Spontaneously Hypertensive Rats
- Effects of Long-Term Antihypertensive Therapy on Physical Fitness of Men with Mild Hypertension.
- Prediction of Progression of Left Ventricular Hypertrophy in Mild Hypertension: 5-Year Observations without Pharmacological Intervention.